Benaroya Research Institute
Benaroya Research Institute (BRI) is one of twenty-two type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Carla Greenbaum, MD, the TrialNet team at BRI is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.
Our Team
Carla Greenbaum, MD
Director, Diabetes Clinical Research Program, TrialNet ChairDr. Greenbaum joined the Benaroya Research Institute (BRI) in 2000, where she is a Member and serves as Director of the Diabetes Research Program and the BRI Clinical Research Center. Dr. Greenbaum serves on the Board of Directors for BRI and is a member of the BRI Institutional Review Board, which provides oversight for clinical studies. She currently serves as Chair of Type 1 Diabetes TrialNet
Sandra Lord, MD
Bao Ng, DNP
Sub-Investigator
Dana VanBuecken, ARNP-BC
Heather White
Anna Barash
Corinna Tordillos
Kim Varner
Nancy Wickstrom
Cassandra Williams
Sadiqa El’Amin-White
RJ Christy
Rishab Kotak
"We want to thank every person who has taken part of research over the past 20 years. Because of their participation, we can now identify the disease in earlier stages, long before symptoms appear. The next step is to find a way to stop the disease from progressing and prevent symptomatic type 1 diabetes." Carla Greenbaum, MD
Regional Affiliates
Affiliates provide opportunities for people who do not live near a TrialNet Clinical Center. The affiliate sites listed below work with BRI to offer convenient participation in our research programs
Research Studies
The following studies are actively recruiting participants. Please click on the study title to learn more. For those interested in participation, contact us for more information.
If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More
Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More
We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D. Details
TrialNet tested the drug abatacept to see if it could delay or prevent stage 1 T1D (two or more diabetes-related autoantibodies, but normal blood sugar) from progressing to stage 2 (abnormal blood sugar) or to stage 3 (clinical diagnosis). In an earlier study in people newly diagnosed (stage 3), participants treated with abatacept had 59% better insulin production and a 9.6-month average delay in progression of insulin loss compared to those who received placebo. That difference extended out to 3 years. Details
If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More
TrialNet is testing the safety of a new treatment, NNC0361-0041, in adults diagnosed with type 1 diabetes (T1D) in the past 48 months. This is a Phase 1 study, which means it is the first time this treatment is being tested for safety in people. If this study results in no safety concerns, we plan to conduct a larger study to see if this same treatment can slow down or stop T1D in people at high risk, before clinical diagnosis. More
